IL23R and autoimmune disease: Our studies support future research either in the production or clinical trials of therapeutic antibodies targeting IL-23/IL-17 axis receptors in SLE, particularly IL-23R, and the inhibition of IL-23/IL-17 receptors is a promising therapeutic strategy in this autoimmune disorder.